{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-132308","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2024-12-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.555551+00:00","generated_at":"2026-05-28T22:42:05.265546+00:00","sec_items":["1.01","5.03","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"KALA BIO raises $10.75M in private placement; cash runway into Q1 2026","bullets":["Gross proceeds of $10.75M from 1,340,603 common shares at $6.44 and 3,286 Series I preferred shares at $644.","Series I preferred convertible into 100 common shares per share; beneficial ownership limitation of 9.99% (up to 19.99%).","Cash resources, including proceeds, expected to fund operations into Q1 2026; net proceeds to advance KPI-012 for PCED.","Phase 2b CHASE trial enrollment over 80% complete; topline data expected Q2 2025.","Participation from new and existing investors including SR One, Cormorant, Woodline."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-132308","json":"https://secwatch.observer/filing/0001104659-24-132308.json","markdown":"https://secwatch.observer/filing/0001104659-24-132308.md","text":"https://secwatch.observer/filing/0001104659-24-132308.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000110465924132308/0001104659-24-132308-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000110465924132308/tm2432193d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T22:42:05.265546+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22f50d1770455a7e8ace42738b89026f4bb586eb","claim":"KALA BIO, Inc.: Filed Certificate of Designations establishing Series I Convertible Non-Redeemable Preferred Stock (effective 2024-12-30).","evidence_excerpt":"On December 30, 2024 (the “Filing Date”), the Company filed a Certificate of Designations, Preferences and Rights of Series I Convertible Non-Redeemable Preferred Stock (the “Certificate of Designations”) with the Secretary of State of the State of Delaware with respect to the Series I Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000110465924132308/0001104659-24-132308-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-12-30"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}